Navigation Links
CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive
Date:5/24/2011

Boston, MA May 24, 2010 CardioCareLive, the world's largest live online cardiology congress presented by the Johns Hopkins University School of Medicine, today announced three new complimentary Continuing Medical Education (CME) Summits to be held over two days on Tuesday June 28th and Wednesday June 29th offering topics of interest to cardiovascular care and internal medicine and family care physicians in Atrial Fibrillation, Interventional Cardiology and Lipids. The Atrial Fibrillation Summit at CardioCareLive is supported by educational grants from Bristol-Myers Squibb and Pfizer, Inc. and Boehringer Ingelheim, the Interventional Cardiology Summit is supported by an educational grant from Daiichi/Lilly and the Lipids Summit at CardioCareLive is supported by an educational grant from Merck & Co.

The Cardiovascular Research Foundation is joining Johns Hopkins in presenting four sessions within the Interventional Cardiology Summit beginning at 2:00 PM EDT on Tuesday June 28th. The Cardiovascular Research Foundation's mission is to improve the survival and quality of life for people with cardiovascular disease through research and education.

CardioCareLive enables physicians, nurse practitioners and physician assistants and other healthcare practitioners to stay current on advances in cardiovascular care at no cost by viewing streaming video CME presentations featuring recognized cardiology experts from the convenience of any computer. A total of 12 AMA PRA Category I Credits will be available during the live programming June 28th and June 29th in addition to the 13 AMA PRA Category I Credits currently available on demand in enduring format at CardioCareLive. It is complimentary to register and attend any program at CardioCareLive.

Physicians from the nation's most respected teaching hospitals and cardiology care associations will act as activity directors for the three programs over two days at CardioCareLive. Dr. Roger Blumenthal, Professor of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, will be the Activity Director for the Atrial Fibrillation, Interventional Cardiology and Lipids Summits. He will be joined by Dr. Gregg Stone, Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center, and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation, as activity director for the Interventional Cardiology summit. Dr. Chris Cannon, Associate Professor of Medicine at Harvard Medical School and Associate Physician, Cardiovascular Division at Brigham and Women's Hospital, will join Dr. Roger Blumenthal as Activity Director for the Atrial Fibrillation and Lipids summits.

Live programming begins on Tuesday June 28th at 9:00 AM EDT and again on Wednesday June 29th at 11:00 AM EDT, with individual presentations beginning on the hour. Practitioners who attend live may take advantage of interactive capabilities by texting in questions to be addressed live -online by presenting faculty. Each session will be available in on demand (enduring) format as soon as the session concludes. The agenda features the following topics:

ATRIAL FIBRILLATION
Are We Getting Better at Identifying AF Patients at High Risk of Stroke?
Stroke Prevention in AF: Putting the Current Guidelines Into Clinical Practice
New Frontiers in Stroke Prevention in the AF Setting: A Focus on Unmet Patients' Needs
Optimizing Therapy Choices to Prevent Stroke in Patients With AF

INTERVENTIONAL CARDIOLOGY
In partnership with the Cardiovascular Research Foundation
Clinical Perspectives in Stent Thrombosis: A Focus on Prevention and Management
Optimizing Performance Measures to Improve STEMI Outcomes Syndromes
Who Is at Risk of Antiplatelet Resistance: From Genetics to Clinical Relevance
Stents in Patients With Stable Angina: Overused or Misunderstood?

LIPIDS
Optimizing Current Strategies with Statins: A Focus on New Evidence
Moving Beyond Statin Treatment in Dyslipidemias
Emerging Therapies and Their Role in Comprehensive Lipid Management
Management of Residual Cardiovascular Risk


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Women More Likely to Fail Treatment for Atrial Fibrillation
2. In Tests, Implanted Monitor Detects Atrial Fibrillation
3. Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation
4. People with diabetes are at higher risk of atrial fibrillation
5. BioSTARTM device achieves 90 percent closure rate for atrial septal defect in children
6. Having Relative With Atrial Fibrillation Raises Own Risk
7. New trial studies link between stroke and atrial fibrillation
8. Heavy Drinking May Boost Risk for Atrial Fibrillation
9. Blood Pressure Drug Does Not Help Those With Atrial Fibrillation
10. Data evaluates rehospitalization and cost burden of AFib/atrial flutter
11. Cryoablation used to successfully treat atrial fibrillation at the Montreal Heart Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – Edition ... has initiated a second print-run of its lavish luxury travel coffee table book. ... weighs in at more than six kilos, retails at EUR 1,000 per copy and ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis ... University of Pittsburgh points to eight genes that may explain why susceptibility to one ... the results of a study published today in the journal npj Schizophrenia. , ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is ... University predict that 47 percent of all jobs in the United States may be ... “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is drawing to ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An Australian ... account of his paramedic experiences. Schanssema describes the tragedies he saw, as well as ... overcome them. , Schanssema, initially unsure of the career path he wanted to take, ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)...  Xynomic Pharmaceuticals, Inc., an oncology drug research ... acquired exclusive worldwide rights to develop, manufacture and ... targeting hematological and solid tumors. To ... 2 clinical trials of Abexinostat in US, EU ... been completed, demonstrating that Abexinostat is clinically active ...
(Date:2/23/2017)... SEOUL , Südkorea, 23. Februar 2017 ... LED für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache ... kurzwellige ultraviolette Strahlung im Bereich zwischen 200 und 280 nm ... Ausbreitung von Bakterien, indem es ihre DNA zerstört. Das ... 280 nm. ...
Breaking Medicine Technology: